MARGIT M. JANÁT-AMSBURY is holding a faculty appointment as Assistant Professor with the Division of Gynecologic Oncology in Department of Gynecology and Obstetrics, at the University of Utah. She received her M.D., Ph.D. in Gynecologic Oncology at the University of Cologne, Germany, did her clinical fellowships at Mount Sinai Hospital, New York, at the Academisch Ziekenhuis Maastricht at the University of Maastricht in the Netherlands and conducted her postdoctoral research studies at the University of Utah.
Prof. Janát-Amsbury focuses on the development of novel polymeric drug-, and gene carriers for clinical use in cancer therapy focusing mainly on gynecological malignancies. Her laboratory specializes in the design and development of innovative delivery systems and linking the areas of nano-medicine, macromolecular drug delivery, pharmaceutics and bioengineering to clinical applications. Delivery systems investigated by the Janát-Amsbury group are tailored to the tumor immunology of gynecological malignancies, including breast cancer and also target other areas of interest from the broad field of Obstetrics and Gynecology, including reproductive endocrinology and infertility, maternal fetal medicine as well as benign conditions as uterine fibroids and endometrioses.
Prof. Janát-Amsbury's research aims to develop novel diagnostic and therapeutic tools specifically for ovarian, endometrial and cervical cancer. She has extensive clinical trial experience in oncology as an investigator and as a clinician in Europe and the United States and also held appointments at the University of Maastricht in the Netherlands and at Baylor College of Medicine in Houston, Texas, where she focused on translational research, being a lead-investigator in the first ever in humans applied polymeric IL-12 delivery system conducting a Phase 1 clinical trial in humans treating patients with recurrent ovarian cancer under a gene therapy protocol she developed.
Prof. Janát-Amsbury was recruited back to the University of Utah by the department of gynecology and obstetrics, division of gynecologic oncology in fall 2007 where she focuses on establishing a translational research program linking basic scientists and clinicians together for the benefit of researching new paths to diagnose and cure gynecologic cancers.